101 related articles for article (PubMed ID: 28422250)
21. Efficient VEGF targeting delivery of DOX using Bevacizumab conjugated SiO
Zhu R; Wang Z; Liang P; He X; Zhuang X; Huang R; Wang M; Wang Q; Qian Y; Wang S
Acta Biomater; 2017 Nov; 63():163-180. PubMed ID: 28923539
[TBL] [Abstract][Full Text] [Related]
22. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
23. Exploring cancer metastasis prevention strategy: interrupting adhesion of cancer cells to vascular endothelia of potential metastatic tissues by antibody-coated nanomaterial.
Xie J; Dong H; Chen H; Zhao R; Sinko PJ; Shen W; Wang J; Lu Y; Yang X; Xie F; Jia L
J Nanobiotechnology; 2015 Feb; 13():9. PubMed ID: 25643843
[TBL] [Abstract][Full Text] [Related]
24. Fluorescent carbon dot-gated multifunctional mesoporous silica nanocarriers for redox/enzyme dual-responsive targeted and controlled drug delivery and real-time bioimaging.
Wang Y; Cui Y; Zhao Y; He B; Shi X; Di D; Zhang Q; Wang S
Eur J Pharm Biopharm; 2017 Aug; 117():105-115. PubMed ID: 28363599
[TBL] [Abstract][Full Text] [Related]
25. Ex vivo and in vivo capture and deactivation of circulating tumor cells by dual-antibody-coated nanomaterials.
Xie J; Gao Y; Zhao R; Sinko PJ; Gu S; Wang J; Li Y; Lu Y; Yu S; Wang L; Chen S; Shao J; Jia L
J Control Release; 2015 Jul; 209():159-69. PubMed ID: 25933713
[TBL] [Abstract][Full Text] [Related]
26. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
27. Zwitterionic mesoporous nanoparticles with a bioresponsive gatekeeper for cancer therapy.
Khatoon S; Han HS; Lee M; Lee H; Jung DW; Thambi T; Ikram M; Kang YM; Yi GR; Park JH
Acta Biomater; 2016 Aug; 40():282-292. PubMed ID: 27063494
[TBL] [Abstract][Full Text] [Related]
28. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
29. One-pot green synthesis of doxorubicin loaded-silica nanoparticles for in vivo cancer therapy.
Jiang S; Hua L; Guo Z; Sun L
Mater Sci Eng C Mater Biol Appl; 2018 Sep; 90():257-263. PubMed ID: 29853089
[TBL] [Abstract][Full Text] [Related]
30. Multifunctional mesoporous silica nanoparticles modified with tumor-shedable hyaluronic acid as carriers for doxorubicin.
Zhang J; Sun Y; Tian B; Li K; Wang L; Liang Y; Han J
Colloids Surf B Biointerfaces; 2016 Aug; 144():293-302. PubMed ID: 27107383
[TBL] [Abstract][Full Text] [Related]
31. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
32. Cytochrome c end-capped mesoporous silica nanoparticles as redox-responsive drug delivery vehicles for liver tumor-targeted triplex therapy in vitro and in vivo.
Zhang B; Luo Z; Liu J; Ding X; Li J; Cai K
J Control Release; 2014 Oct; 192():192-201. PubMed ID: 25034575
[TBL] [Abstract][Full Text] [Related]
33. Correction: A novel nanomissile targeting two biomarkers and accurately bombing CTCs with doxorubicin.
Gao Y; Xie X; Li F; Lu Y; Li T; Lian S; Zhang Y; Zhang H; Mei H; Jia L
Nanoscale; 2018 May; 10(18):8870-8871. PubMed ID: 29707724
[TBL] [Abstract][Full Text] [Related]
34. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts.
Zhong Y; Zhang J; Cheng R; Deng C; Meng F; Xie F; Zhong Z
J Control Release; 2015 May; 205():144-54. PubMed ID: 25596560
[TBL] [Abstract][Full Text] [Related]
35. High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin.
Fu A; Ma S; Wei N; Tan BX; Tan EY; Luo KQ
Oncotarget; 2016 Aug; 7(31):50239-50257. PubMed ID: 27384484
[TBL] [Abstract][Full Text] [Related]
36. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
37. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxicity of folic acid conjugated hollow silica nanoparticles toward Caco2 and 3T3 cells, with and without encapsulated DOX.
Patel K; Sundara Raj B; Chen Y; Lou X
Colloids Surf B Biointerfaces; 2016 Apr; 140():213-222. PubMed ID: 26764104
[TBL] [Abstract][Full Text] [Related]
39. Bile acid-conjugated chondroitin sulfate A-based nanoparticles for tumor-targeted anticancer drug delivery.
Lee JY; Chung SJ; Cho HJ; Kim DD
Eur J Pharm Biopharm; 2015 Aug; 94():532-41. PubMed ID: 26149228
[TBL] [Abstract][Full Text] [Related]
40. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
